Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)

Classification criteria for psoriatic arthritis: Development of new criteria from a large international study

William J. Taylor, Dafna D. Gladman, Philip Helliwell et al. · Arthritis & Rheumatism · 2006 · 3.6K citations

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis

Laura C. Coates, Arthur Kavanaugh, Philip J. Mease et al. · Arthritis & Rheumatology · 2016 · 899 citations · Full text

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Kim Papp, Kristian Reich, Craig L. Leonardi et al. · Journal of the American Academy of Dermatology · 2015 · 649 citations · Full text

Autoimmune Disease, Medicine, Phase Iii +7

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

C. Paul, Jennifer Clay Cather, Melinda Gooderham et al. · British Journal of Dermatology · 2015 · 464 citations · Full text

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

Arthur Kavanaugh, Philip J. Mease, Juan J. Gómez‐Reino et al. · Annals of the Rheumatic Diseases · 2014 · 435 citations · Full text